The carboxyl-terminal one-third of the Epstein-Barr virus nuclear antigen (EBNA-1) encoded by the BamHI restriction fragment K 
related diseases can be an important indicator for clinical evaluation and treatment. For example, the presence of IgA antibodies to the viral capsid antigen is virtually diagnostic for undifferentiated nasopharyngeal carcinoma (1) (2) (3) (4) , and the antibody response to the early-antigen complex forms a prognostic indicator of the outcome of this disease (5) . We anticipate that the value of such monitoring would be enhanced if assays based on total infected cell extracts could be complemented by quantitative ELISAs measuring the antibody response to individual viral proteins.
All cells carrying EBV DNA, including the tumor cells in Burkitt lymphoma and nasopharyngeal carcinoma, express the nuclear antigen EBNA. Two separate components of EBNA have been identified by serology (6, 7) . The EBNA-1 polypeptide was shown by DNA transfection experiments to be synthesized from the BamHI restriction fragment K (8, 9) . Within BamHI K lies a 2.0-kilobase (kb) open reading frame, 700 bp of which is composed exclusively of three repeated triplet sequences, GGA, GGG, and GCA (10, 11) . The size of the repeat array varies among different EBV isolates and the EBNA polypeptide shows corresponding size variations ranging from 68 kDa to 84 kDa (12) (13) (14) . Hennessy and Kieff (6) used rabbit antiserum raised against a bacterially synthesized product of the repeat array to demonstrate that these sequences are translated in the EBNA polypeptide as a stretch of repeated glycine and alanine residues. Both this antiserum and one produced against a synthetic peptide containing -Gly-Gly-Ala- (15) recognized EBNA in immunofluorescence assays and in immunoblot analyses. However, the repeat DNA sequence has homology to cellular DNA (16) , and antisera to the -Gly-Gly-Ala-peptides also reacted with cellular proteins (15, 17) . The EBNA protein is known to have DNA-binding properties and to be required in trans for maintenance of the multicopy circular state of transfected DNA containing the EBV plasmid replication origin region (18) .
Waldman et al. (19) described the use of high-expression plasmids to synthesize large quantities of herpes simplex virus thymidine kinase in bacteria. In this report, we describe the bacterial synthesis of a 28-kDa fusion polypeptide that contains the carboxyl-terminal fragment of EBNA and lacks the Gly-Gly-Ala repeat region. This 28-kDa EBNA, which can be obtained in large quantity and is easily purified, was used to generate anti-EBNA monospecific and monoclonal antibodies and to develop a sensitive ELISA for quantitating anti-EBNA antibodies in human serum.
MATERIALS AND METHODS
Cell Lines. Mouse fibroblast cell lines synthesizing EBNA (LEK cells) were established by transfecting LTK-cells with the EBV (P3HR-1) BamHI K fragment inserted into pSV2neo (20) and selecting for G418 (geneticin) resistance and EBNA expression. LTK-cells and LEK cells were grown in Dulbecco's modified Eagle's medium, and the lymphoblastoid lines Raji, P3HR-1, and BJAB were grown in RPMI 1640. All media were supplemented with 10% fetal calf serum (Hyclone, Sterile Systems, Logan, UT).
Abbreviations: EBV, Epstein-Barr virus; EBNA, EBV-encoded nuclear antigen; ACIF, anticomplement immunofluorescence; kb, kilobase(s); bp, base pair(s).
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Plasmid Construction. The high-expression plasmid pHE6 ( Fig. 1) contains essential regions of the plasmid pGM10 (19) inserted into a derivative of the plasmid pUC8 (21) . Specifically, the Hae II-Sma I region of pUC8 was replaced with two adjacent segments of X phage DNA (22) : that from the Hae II site at base 37,061 to the Bgl II site at base 38,103 and that from the Bgl II site at base 35,711 to the Hpa I site at base 35,261. In addition, a synthetic DNA fragment (CCGGATC-CCC) was inserted between the Hpa I site and the GGG ofthe Sma I site of pUC8. Foreign DNA may be inserted into the unique BamHI, Sma I, Sal I, and Pst I restriction sites. Plasmid pHE6 produces polypeptides from inserted foreign DNA as "run-on" proteins of the X phage N protein. The synthesis of these proteins is regulated by the X temperaturesensitive repressor. A 2236-bp Sma I subfragment of EBV (P3HR-1) BamHI fragment K was inserted at the Sma I site of pHE6 in both the sense and the antisense directions to produce plasmids pNAK28 and pNAK28- (Fig. 1) .
Purification of Bacterially Synthesized 28-kDa EBNA. Escherichia coli K-12 DH1 containing pNAK28 were induced to synthesize the 28-kDa EBNA by a shift in temperature from 30TC to 42TC as described (19 0-250 mM sodium phosphate (pH 7.5) in 250 mM NaCl/50 mM Tris Cl, pH 7.5.
Antibody Preparation. New Zealand White rabbits were injected subcutaneously with 300 ,tg of purified 28-kDa EBNA suspended in Freund's complete adjuvant and given booster injections at 10-to 14-day intervals with 300 ,Ag of 28-kDa EBNA suspended in incomplete adjuvant. Monoclonal antibodies to 28-kDa EBNA were prepared by methods previously described (23) . Briefly, spleen cells from BALB/c mice immunized with 28-kDa EBNA were fused with P3-X63Ag8 myeloma cells. Culture supernatants were screened for antibody capable of immunoprecipitating 28-kDa EBNA, and cells from positive wells were cloned twice in soft agar. The five monoclonal antibodies used in this work (EBNA-2D1, EBNA-3C6, EBNA-6A1, EBNA-6A3, and EBNA-6B1) were all of the IgG1 class and were prepared as ascites fluid.
Immunological Assays for EBNA. Immunological reagents were purchased from Cappel Laboratories (Cochranville, PA) and Bethesda Research Laboratories (Bethesda, MD). For immunofluorescence assays, the cells were fixed in methanol and then incubated with rabbit serum and stained by anticomplement immunofluorescence (ACIF) (24) or with fluorescein isothiocyanate (FITC)-conjugated anti-rabbit IgG. Slides incubated with monoclonal antibodies were stained using biotin-tagged anti-mouse IgG followed by FITC-conjugated streptavidin. Immunoblot analyses were carried out by published procedures (17, 25) . The protein blots were incubated with human, rabbit, or monoclonal serum for 90 min at room temperature, washed, and reacted with the appropriate alkaline phosphatase-tagged anti-IgG antibody. Bands were visualized by incubation with colorproducing substrate (napthol AS-BI, fast blue, and fast violet).
ELISA for Anti-EBNA Antibody. Microtiter plates coated with purified 28-kDa EBNA (40 ng per well in 0.5 M sodium carbonate buffer at pH 9.6) were incubated first with blocking solution (2% normal goat serum in 0.15 M NaCl/0.1 M sodium phosphate, pH 7.4/0.05% Tween 20) orientation (lane A) or in extracts of bacteria containing the pHE6 expression vehicle only (not shown). When pNAK28 extracts were applied to phosphocellulose, most of the protein passed through the column (lane C), but the 28-kDa polypeptide bound and was eluted between 0.5 and 0.6 M NaCl (lane D). Minor contaminants were removed by chromatography on hydroxylapatite (lane E), where the 28-kDa polypeptide was eluted between 120 mM and 160 mM phosphate. This 28-kDa fusion fragment of EBNA comprised -8% of the soluble protein in extracts of induced bacteria containing pNAK28 and it was the only band recognized by EBNA-positive human serum in immunoblots ofthe bacterial extracts (lanes F-J), thus confirming that it represented the product of the inserted EBNA coding region. The purified 28-kDa EBNA polypeptide was used to elicit monospecific and monoclonal antibodies in rabbits and mice, respectively.
Correct Specificity of Rabbit Antiserum and Monoclonal Antibodies Raised Against the 28-kDa EBNA Polypeptide. The reactivity of anti-28-kDa EBNA antisera in indirect immunofluorescence assays is illustrated in Fig. 3 . Positive nuclear fluorescence was detected in EBV-carrying lymphoblastoid cell lines (Fig. 3b) and in the DNA-transfected fibroblast cell line (LEK) expressing EBNA (Fig. 3 a, c , and e), but not in the EBV genome-negative BJAB lymphoblastoid cell line or in the mouse LTK-line from which the LEK transfectants were derived (Fig. 3 d and f) . On LEK cells, EBNA was detectable with the rabbit serum by either the ACIF amplification procedure (Fig. 3a) or more directly with FITC-conjugated anti-rabbit IgG (Fig. 3c) . EBNA was barely detectable by immunofluorescence using individual monoclonal antibodies. However, a pool of five monoclonal antibodies gave positive results in a biotin-streptavidinbased indirect immunofluorescence assay with either EBVcarrying lymphoblastoid cell lines (results not shown) or LEK fibroblasts (Fig. 3e) . The enhanced immunofluorescence obtained by pooling the monoclonal antibodies suggests that the individual antibodies are probably directed against different epitopes.
To demonstrate that the antibodies raised against the 28-kDa EBNA recognized the appropriate intact EBNA polypeptides, we carried out immunoblotting experiments. As shown in Fig. 4 , the rabbit antiserum, individual monoclonal antibodies, and an EBNA-positive human control Detection of EBNA by an immunoblot assay using human or rabbit serum and mouse monoclonal antibodies. Extracts of EBNA-positive (LEK, P3HR-1, and Raji) and EBNA-negative (LTK-and BJAB) cell lines were electrophoresed in a NaDodSO4/ 12.5% polyacrylamide gel and transferred to a nitrocellulose membrane (25) . The protein blots were incubated with dilutions of EBNA-positive, nasopharyngeal carcinoma patient serum (a), rabbit hyperimmune serum (b), or the EBNA-6A3 monoclonal antibody (c) and then reacted with the appropriate alkaline phosphatase-conjugated second antibody. The apparent sizes of the EBNA polypeptides in our gel system (84 and 76 kDa) are somewhat larger than those reported by other investigators (12) (13) (14) .
Proc. Natl. Acad. Sci. USA 82 (1985) I serum all recognized a polypeptide ofapparent molecular size 84 kDa in extracts from P3HR-1 lymphoblasts and in extracts from LEK cells (converted by transfection with the P3HR-1 BamHI K fragment). This 84-kDa band was not present in EBV-negative BJAB lymphoblasts or in LTK-cells. The Raji EJ3NA polypeptide is smaller than that of P3HR-1 (12) and as expected, the rabbit antiserum and the human EBNApositive control serum both immunostained an appropriately smaller protein in Raji cell extracts.
Sensitive ELISA for Examining the Spectrum of Anti-EBNA Antibody in Human Serum. The availability of large quantities of pure 28-kDa EBNA antigen made it feasible to develop a rapid and highly specific ELISA for quantitation of antibody titers in clinical samples. The assay depended upon the carboxyl-terminal portion of EBNA and not just the GlyGly-Ala repeats being immunogenic. A summary of ELISA determinations of anti-28-kDa EBNA IgG in 222 serum samples from normal adults or patients with infectious mononucleosis, rheumatoid arthritis, Burkitt lymphoma, or nasopharyngeal carcinoma is presented in Fig. 5 All Burkitt lymphoma and nasopharyngeal carcinoma. sera tested and 80/83 of the rheumatoid arthritis sera were positive. The titers of the seropositive rheumatoid arthritis and Burkitt lymphoma patients spanned the same range as the normals, but the mpdian titers of these patients were 1:1400 and 1:2400, somewhat higher than that of the normal group. The 10 nasopharyngeal carcinoma sera all showed elevated EBNA titers. The median titer was 1:8000 and 80% of the samples had titers greater than 1:5000, in contrast to the normal group where only 8% of the samples fell into this category. Although the infectious mononucleosis sera were EBNA-negative by ACIF, 15 of the 19 samples had low but demonstrable anti-EBNA antibody titers by ELISA. The median titer for these sera was 1:50. In general, an ELISA titer of 1:500 was approximately equivalent to the threshold (1:2) titerfor the more subjective ACIF assay using Raji cells.
DISCUSSION
Characterization ofthe EBNA polypeptide and elucidation of its functions in latency and immortalization have been hampered by the low abundance of the protein in lymphoblastoid cells and a lack of specific immunological reagents: for example, EBNA is traditionally detected using EBVseropositive human serum and complement-mediated immunofluorescence. The bacterial 28-kDa EBNA polypeptide now provides an abundant, easily purified EBNA reagent likely to be of considerable value for both clinical evaluation and for basic studies of the role of EBNA in EBV latency. The availability of this protein permitted the preparation of both rabbit polyclonal and mouse monoclonal antibodies that gave the typical EBNA staining pattern by ACIF on EBVcarrying lymphocytes and on LEK fibroblast cells expressing EBNA. The staining obtained with a pool of monoclonal antibodies was less intense than that observed with the rabbit serum and ACIF but has the advantage of being complementindependent. Both the rabbit and the individual monoclonal antibodies also specifically recognized the intact BamHI fragment K-encoded EBNA polypeptide on immunoblots.
The monoclonal antibodies were originally selected not for immunofluorescence but on the basis of their ability to immunoprecipitate the 28-kDa EBNA polypeptide, and they may also prove valuable as specific reagents for immunoprecipitation.
The 28-kDa EBNA polypeptide used here contains only the carboxyl-terminal one-third of the EBNA-1 protein and lacks the Gly-Gly-Ala repeats. Therefore, the potential problem of crossreactivity of the antibodies with cellular proteins containing glycine plus alanine-rich regions (15, 17) was eliminated. Furthermore, these antibodies can be used as specific probes for examining the function of the carboxyl-terminal region of the protein. Of particular relevance in this regard is the discovery that the 28-kDa, bacterially synthesized carboxyl terminus of EBNA is a sequence-specific DNAbinding domain that interacts with the plasmid maintenance region (orip) of the EBV genome (30) .
The increased sensitivity and objectivity of an ELISA make this procedure an attractive alternative to immunofluorescence assays for determining antibody status.
Previous reports of the use of ELISAs to measure anti-EBV antibody titers (27) (28) (29) earlier studies, the source of EBNA antigen was either total extracts (27) The sensitivity of the bacterial antigen ELISA is illustrated by the finding that nasopharyngeal carcinoma patient sera with ACIF titers between 1:320 and 1:640 gave ELISA titers between 1:50,000 and 1:100,000. However, the titers of individual serum samples measured by 28-kDa EBNA ELISA were not always directly comparable to those measured by ACIF, which may be a reflection of the presence in some human sera of antibodies against other EBNAs (6, 7) and against epitopes on the amino-terminal two-thirds of BamHI fragment K-encoded EBNA. A similar observation was made by Dillner et al. (15) , who used an ELISA based on a synthetic Gly-Gly-Ala-containing polypeptide. The bacterial antigen ELISA also showed complete specificity in that EBNA titers were observed only in individuals who showed serological evidence for prior exposure to EBV. The 12 normal sera and 3 rheumatoid arthritis patient sera that were EBNA negative in this assay were also negative for the viral capsid antigen by immunofluorescence. In addition, the 28-kDa EBNA ELISA appeared to be unaffected by the presence of nonspecific anti-nuclear antibodies which prevent a determination of EBNA titer in the ACIF assay. The 28-kDa E3NA ELISA is thus both sensitive and specific. Finally, as would be necessary to validate the use of the 28-kDa EBNA polypeptide as an ELISA reagent, the overall pattern of ELISA determined anti-28-kDa EBNA titers was consistent with results obtained previously by others using ACIF (26) or the earlier ELISAs (27) (28) (29) . Specifically, low EBNA titers were observed in the early stages of infectious mononucleosis, whereas nasopharyngeal carcinoma patients all had high EBNA titers and some Burkitt lymphoma patients had high EBNA titers, while others were in the normal range. The rheumatoid arthritis patients gave a similar range and distribution of anti-EBNA titers to those of seropositive but healthy individuals except for some skewing of the arthritis patient samples towards higher titers.
The anti-28-kDa EBNA ELISAs also provided some insight into the humoral immune response to EBNA. The sensitivity of the bacterial antigen ELISA measurements for anti-EBNA antibodies enabled us to quantitate anti-EBNA antibody in all individuals who were seropositive for the EBV viral capsid antigen. The anti-EBNA titers were spread over a three-orders-of-magnitude range of values, with the highest titers in the normal and rheumatoid arthritis groups being equivalent to those seen in nasopharyngeal carcinoma patient sera. We calculated that these high-titer individuals possess antibodies to EBNA at concentrations up to 1 mg/ml of serum, representing >1% of the total IgG content. We conclude from the anti-28-kDa EBNA ELISA data that EBNA, and in particular the carboxyl-terminal domain of EBNA, is extremely immunogenic in man. The high titers of anti-EBNA antibody measured by this assay raise the possibility that the degree of exposure of the immune system to EBNA, in normal individuals as well as those with ongoing disease, may have been underestimated previously because of the insensitivity of the ACIF assay for EBNA.
